Juvenile RA/Pediatric Rheumatology

Sangeeta Sule, M.D.

Abstract 659: Long-Term Efficacy and Safety of Adalimumab in Children with Juvenile Rheumatoid Arthritis (JRA): 48 Week Results

Abstract 718: Preliminary Evidence for Bioactivity of IL-1 Trap (Rilonacept), A Long Acting IL-1 Inhibitor, in Systemic Juvenile Idiopathic Arthritis (SJIA)

Abstract 719: Assessment of Open Label Co-Stimulation Blockade with Abatacept in Children and Adolescents with Active Juvenile Idiopathic Arthritis (JIA)

Abstract 722: Rapid Improvement of Signs and Symptoms Associated with Systemic Juvenile Idiopathic Arthritis (sJIA) by Interleukin-6 (IL-6) Blockade - Results from a Tocilizumab sJIA Phase III Clinical Trial

Abstract 723: A Randomized, Multi-Center, Blinded, Placebo-Controlled Study With an Open-label Run-in Period to Evaluate Anakinra in Polyarticular-Course Juvenile Rheumatoid Arthritis

Abstract Number 1700 - Mycophenolate Mofetil (MMF) in Juvenile Dermatomyositis

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.